<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03832140</url>
  </required_header>
  <id_info>
    <org_study_id>PRURIGAMMA (29BRC18.0192)</org_study_id>
    <nct_id>NCT03832140</nct_id>
  </id_info>
  <brief_title>Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy</brief_title>
  <acronym>PRURIGAMMA</acronym>
  <official_title>Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pruritus is most often secondary to dermatitis but can also occur without skin lesions, it is&#xD;
      called pruritus sine materia. The causes of pruritus sine materia are various: haematological&#xD;
      (myeloproliferative neoplasia ...), hepatic (cholestasis ...), renal (chronic renal failure,&#xD;
      dialysis), endocrine (iron deficiency ...), secondary to drug intake ... or idiopathic when&#xD;
      no cause is found.&#xD;
&#xD;
      Gammapathies are among the causes of pruritus sine materia, and as such electrophoresis of&#xD;
      serum proteins is usually part of the pruritus assessment to look for monoclonal gammopathy&#xD;
      (MGUS, multiple myeloma, Waldenstr√∂m disease). However, there is very little data on the&#xD;
      frequency of pruritus in patients with monoclonal gammopathy and the characteristics of this&#xD;
      pruritus. So the aim of this study is to compare the frequency of pruritus between patients&#xD;
      with monoclonal gammapathy and controls&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2019</start_date>
  <completion_date type="Actual">November 19, 2019</completion_date>
  <primary_completion_date type="Actual">November 19, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of pruritus</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">281</enrollment>
  <condition>Pruritus</condition>
  <condition>Monoclonal Gammopathy</condition>
  <arm_group>
    <arm_group_label>Patients with monoclonal gammopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with a normal plasma protein electrophoresis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had serum protein electrophoresis at Brest CHRU between 2014 and 2017, with&#xD;
        and without gammapathy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for case :&#xD;
&#xD;
        Major patient Realized Serum protein electrophoresis between 2014 and 2017 Hematology&#xD;
        follow-up at Brest CHR Positive monoclonal gammopathy Non-opposition formulated&#xD;
&#xD;
        Inclusion Criteria for Control :&#xD;
&#xD;
        Major patient Realized Serum protein electrophoresis between 2014 and 2017 Hematology&#xD;
        follow-up at Brest CHR Negative gammopathy Non-opposition formulated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Minor patient Major protected Patient with another haemopathy secreting a monoclonal&#xD;
        immunoglobulin (lymphoma, LLC ...) Physical or mental incapacity Refusal to participe&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after the publication of result and ending three years maximum following the last visit of the last patient</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. requestors will be required to sign and complete a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

